Moderna had earlier posted a loss of $2.52 per share a year earlier, while analysts expected a loss of $3.96 per share.

Moderna shares rose 9% on Wednesday after it settled a long-running legal battle over the technology that made its COVID-19 vaccine possibl...

Moderna is set to reduce its global workforce by roughly 10%, aiming for under 5,000 employees by year's end, as it accelerates cost-cuttin...

Moderna had said earlier this year it expects operating costs to be between $4.7 billion and $5 billion for 2027. MRNA stock, which has los...

The Nasdaq-100 is currently one of the most closely-monitored stock indexes over the past week, owing to its sudden fluctuations at the US ...

Shares of leading vaccine producers, such as Pfizer and Moderna, experienced notable drops after Robert F. Kennedy Jr. was announced as Pre...

Moderna shares plummeted on Thursday after it announced it would be able to supply only 700 million to 800 million vaccine doses this year,...

Moderna's announcement comes after pharmaceutical giant Pfizer Inc. said its COVID-19 vaccine remained effective months after the second do...

Moderna shares rose 6% in extended trade after the announcement. The COVID-19 vaccine maker's stock has surged over 150% this year, elevati...

Sisodia said all the 400 vaccination sites for the 18-44 age group have been closed in Delhi after the vaccine stock was over, while the ce...

Earlier this week, larger rival Pfizer Inc said it expects $26 billion in sales of its COVID-19 vaccine this year.

"As we look forward to next year, we just see so much need for primary vaccine, we are hearing it all over the world, and also boosters," M...

Moderna jumped as much as 17% in New York Tuesday. The stock has surged about 73% and added more than $28 billion in market value over the ...

Together with Pfizer Inc's vaccine, also shown to be more than 90% effective, and pending more safety data and regulatory review, the Unite...

The bar was raised for markets to rally following an announcement by Pfizer Inc. that its vaccine protected 90 per cent of Covid-19 cases i...

Wipro founder Azim Premji is an investor in Moderna, the firm that has emerged a frontrunner for Covid vaccine.

The Cambridge, Massachusetts-based company said the vaccine candidate, mRNA-1273, appeared to produce an immune response in eight people wh...